Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 6.3% – Still a Buy?

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s share price shot up 6.3% during mid-day trading on Thursday . The stock traded as high as $10.63 and last traded at $10.65. 457,419 shares were traded during trading, a decline of 52% from the average session volume of 952,240 shares. The stock had previously closed at $10.02.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Chardan Capital initiated coverage on Stoke Therapeutics in a report on Friday, December 20th. They set a “buy” rating and a $24.00 target price on the stock. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Trading Up 5.8 %

The company has a fifty day moving average of $11.25 and a 200-day moving average of $12.83. The company has a market capitalization of $561.48 million, a price-to-earnings ratio of -5.05 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. As a group, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.03 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In related news, CEO Edward M. Md Kaye sold 6,786 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $88,150.14. Following the transaction, the chief executive officer now owns 61,885 shares in the company, valued at approximately $803,886.15. This trade represents a 9.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 9,696 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $123,914.88. Following the completion of the sale, the general counsel now directly owns 35,142 shares of the company’s stock, valued at $449,114.76. This trade represents a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock valued at $809,421 over the last 90 days. 11.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

Hedge funds have recently made changes to their positions in the company. Intech Investment Management LLC purchased a new stake in shares of Stoke Therapeutics in the 3rd quarter valued at approximately $160,000. The Manufacturers Life Insurance Company raised its position in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after purchasing an additional 1,994 shares during the period. Mesirow Financial Investment Management Inc. acquired a new position in Stoke Therapeutics during the third quarter worth $192,000. Profund Advisors LLC purchased a new position in shares of Stoke Therapeutics during the second quarter worth $201,000. Finally, Rhumbline Advisers raised its holdings in shares of Stoke Therapeutics by 14.3% in the 2nd quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock valued at $647,000 after buying an additional 5,990 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.